Select Language
TL1A
TL1A Overview
| English Name | Tumor necrosis factor superfamily member 15 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 18 | Target Synonym | VEGI192A，Vascular Endothelial Cell Growth Inhibitor，TNF Superfamily Ligand TL1A，TNFSF15，Tumor Necrosis Factor (Ligand) Superfamily， Member 15，Vascular Endothelial Growth Inhibitor-192A，VEGI，TL1A，Tumor Necrosis Factor Ligand 1B，TNLG1B，TNF Superfamily Member 15，Tumor Necrosis Factor Superfamily Member 15，TL1，TNF Ligand-Related Molecule 1，Tumor Necrosis Factor Ligand Superfamily Member 15，MGC129934，MGC129935 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Tumor necrosis factor superfamily member 15 |
| Target Synonym | VEGI192A，Vascular Endothelial Cell Growth Inhibitor，TNF Superfamily Ligand TL1A，TNFSF15，Tumor Necrosis Factor (Ligand) Superfamily， Member 15，Vascular Endothelial Growth Inhibitor-192A，VEGI，TL1A，Tumor Necrosis Factor Ligand 1B，TNLG1B，TNF Superfamily Member 15，Tumor Necrosis Factor Superfamily Member 15，TL1，TNF Ligand-Related Molecule 1，Tumor Necrosis Factor Ligand Superfamily Member 15，MGC129934，MGC129935 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 18 |
| Highest Development Stage | Phase 3 Clinical |
TL1A Product List
- Product Category
Protein (13)Cell (5)Kits (2)
- Product Status
Launched (19)In Research (1)
- Species
Human (12)Cynomolgus / Rhesus macaque (2)Mouse (3)Rat (1)Rabbit (1)Cynomolgus (1)
- Tag
His Tag (9)His Tag & Avi Tag (2)- (7)Fc Tag (1)Avi Tag & His Tag (1)
- Conjugate
Unconjugated (10)Biotin-labeled (3)- (7)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT TLA-H5243 |  Human | HEK293 | Human TL1A / TNFSF15 Protein, His Tag, active trimer, low endotoxin (MALS verified) |  |  |  |
HOT TLA-H52Q1 | Human | HEK293 | Biotinylated Human TL1A / TNFSF15 Protein, His,Avitag™ |  | | |
HOT TLA-M5243 |  Mouse | HEK293 | Mouse TL1A Protein, His Tag, low endotoxin (HPLC-verified) |  | | |
HOT TLA-C5241 |  Cynomolgus / Rhesus macaque | HEK293 | Cynomolgus/Rhesus macaque TL1A / TNFSF15 Protein, His Tag, low endotoxin (MALS verified) |  | | |
CEA-C090 | Human | - | Human TL1A/TNFSF15 ELISA Kit | |||
CHEK-ATP142 | Human | HEK293 | HEK293/Human TL1A Stable Cell Line |  | ||
CHEK-ATP198 | Human | HEK293 | HEK293/Membrane-Bound human TL1A Stable Cell Line | | ||
CRAJ-STP232 | Human | Raji | Raji/Human TL1A Stable Cell Line | | ||
SCRAJ-STT204 | Human | Raji | Raji/Membrane-Bound Human TL1A Stable Cell Line | | ||
TLA-H5244 | Human | HEK293 | Human TL1A / TNFSF15 Protein, His Tag, low endotoxin (MALS verified) |  | | |
Total: 20
- 1
- 2
TL1A Background
TNF-like cytokine 1A (TL1A) and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3) are members of the TNF and TNF receptor superfamilies of proteins, respectively. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects not only the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. Whereas, DcR3 restricts the function of the TL1A/DR3 complex: attenuating T-cell activation and downregulating the secretion of pro-inflammatory cytokines. Together with DR3 and DcR3, TL1A constitutes a cytokine system that actively interferes with the regulation of immune responses.
TL1A Synonyms
TL1A, VEGI, TNFSF15
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Duvakitug | TEV-48574; TEV-'574; TEV'574; SAR447189; SAR-447189; TEV574; TEV-574 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Asthma; Colitis, Ulcerative; Crohn Disease | Details |
| Tulisokibart | PRA-023; MK-7240; PRA023 | Phase 3 Clinical | Merck Sharp & Dohme LLC, Prometheus Biosciences Inc | Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Colitis, Ulcerative; Crohn Disease; Hidradenitis Suppurativa; Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Non-radiographic axial spondyloarthritis; Scleroderma, Diffuse; Spondylitis, Ankylosing | Details |
| Afimkibart | PF-06480605; PF 6480605; RVT-3101; RG-6631; RO-7790121 | Phase 3 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Dermatitis, Atopic; Inflammatory Bowel Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| RO-7837195 | RO-7837195; RO7837195 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative | Details |
| PF-07261271 | RG-6730; PF-07261271 | Phase 2 Clinical | Pfizer Inc | Inflammatory Bowel Diseases | Details |
| SPY0-72 | SPY002-072; SPY0-72 | Phase 2 Clinical | Spyre Therapeutics Inc | Arthritis, Psoriatic; Arthritis, Rheumatoid; Axial Spondyloarthritis; Joint Diseases; Rheumatic Diseases | Details |
| XmAb-942 | XmAb942; XmAb-942 | Phase 2 Clinical | Xencor Inc | Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| BCD-261 | BCD-261 | Phase 2 Clinical | BIOCAD JSC | Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases | Details |
| next-generation anti-TL1A mAb (Pfizer) | Phase 1 Clinical | Pfizer Inc | Fibrosis; Inflammation | Details | |
| ENV-6946 | ENV-6946 | Phase 1 Clinical | Enveda Biosciences Inc | Inflammatory Bowel Diseases | Details |
| QX-030N | QX030N; CLD-423; QX-030N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Autoimmune Diseases; Inflammatory Bowel Diseases | Details |
| HXN-1001 | HXN-1001 | Phase 1 Clinical | Helixon Ltd | Inflammatory Bowel Diseases; Psoriasis | Details |
| GR-2303 | GR-2303 | Phase 1 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd | Inflammatory Bowel Diseases | Details |
| SSGJ-627 | SSGJ-627; SSGJ627 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Colitis, Ulcerative | Details |
| SPY-002 | SPY002-091; SPY002 072; SPY-002; PR-010 | Phase 1 Clinical | Paragon Therapeutics Inc | Details | |
| ABS-101(Absci) | ABS-101(Absci); ABS-101 | Phase 1 Clinical | Absci Corp | Inflammatory Bowel Diseases | Details |
| FG-M701 | FG-M-701; ABBV-701; FG-M701 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Autoimmune Diseases | Details |
| Next-generation anti-TL1A antibody(Telavant) | Phase 1 Clinical | Telavant Inc | Fibrosis; Inflammation | Details |
Product Reviews
S***e2025-09-13
1People LikeWorked all times I have used this product with very reproducible data! Also appreciated the very quick shipping.- A***e2025-04-10 0People LikeI used the TL1A in multiple experiments and the results were always consistent and reproducible. Different lots were used throughout a year long timeline and the results did not differ between lots. When shipping there was not ever any damaged packaging that could impact product quality. I have used Acrobiosystems in my professional career multiple times over multiple years and have always had success :) I will continue to use Acro as a trusted supplier.
- E***r2024-08-08 2People LikeThis protein showed good activity in cell reporter assays and could be used routinely in inhibition assays.
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland